Curaleaf Holdings Inc banner
C

Curaleaf Holdings Inc
CNSX:CURA

Watchlist Manager
Curaleaf Holdings Inc
CNSX:CURA
Watchlist
Price: 6.59 CAD 0.15% Market Closed
Market Cap: CA$4.8B

EV/OCF

75.2
Current
1%
More Expensive
vs 3-y average of 74.8

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
75.2
=
Enterprise Value
CA$5.8B
/
Operating Cash Flow
$56.6m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
75.2
=
Enterprise Value
CA$5.8B
/
Operating Cash Flow
$56.6m

Valuation Scenarios

Curaleaf Holdings Inc is trading above its 3-year average

If EV/OCF returns to its 3-Year Average (74.8), the stock would be worth CA$6.56 (1% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-86%
Maximum Upside
No Upside Scenarios
Average Downside
43%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 75.2 CA$6.59
0%
3-Year Average 74.8 CA$6.56
-1%
5-Year Average 74.4 CA$6.52
-1%
Industry Average 10.4 CA$0.91
-86%
Country Average 11.9 CA$1.05
-84%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CA
Curaleaf Holdings Inc
CNSX:CURA
4.8B CAD 75.2 -5.9
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 51.6 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 23.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15.2 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.1 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.2 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 18.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.5 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 17.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 10.6 16.8
P/E Multiple
Earnings Growth PEG
CA
C
Curaleaf Holdings Inc
CNSX:CURA
Average P/E: 21.9
Negative Multiple: -5.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Higher than 92% of companies in Canada
Percentile
92nd
Based on 1 926 companies
92nd percentile
75.2
Low
0 — 7.9
Typical Range
7.9 — 19.5
High
19.5 —
Distribution Statistics
Canada
Min 0
30th Percentile 7.9
Median 11.9
70th Percentile 19.5
Max 22 577.3

Curaleaf Holdings Inc
Glance View

Market Cap
4.8B CAD
Industry
Pharmaceuticals

Curaleaf Holdings Inc. is a prominent player in the burgeoning cannabis industry. With its roots firmly planted in Massachusetts, Curaleaf quietly grew from a regional entity into a nationwide powerhouse. The company's business model intricately intertwines cultivation, processing, and retail. Curaleaf's vertically integrated structure allows for end-to-end control of its product lifecycle, enhancing both quality assurance and profit margins. They meticulously nurture cannabis plants from seed to harvest, which are then transformed into a range of products, spanning from flower and oil concentrates to edibles and topicals. This comprehensive approach not only supports supply chain efficiency but also significantly bolsters brand consistency and customer satisfaction. Curaleaf's revenue streams flow primarily from its retail operations, where they operate an extensive chain of dispensaries across multiple states. Their strategic acquisitions and mergers have only expanded their footprint, allowing them to tap into diverse markets with varying regulatory landscapes. By establishing a strong retail presence, Curaleaf deftly navigates the complex regulatory frameworks governing cannabis sales, enhancing their market reach and consumer base. Additionally, the company has been proactive in pursuing partnerships and brand extensions, further diversifying its offerings and appealing to a broader audience. This multi-faceted strategy enables Curaleaf to capture a significant share of the growing demand for cannabis-related products, setting a robust foundation for sustained financial growth in an industry poised for expansion.

CURA Intrinsic Value
Not Available
C
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett